FTCNX
Price
$78.25
Change
+$0.04 (+0.05%)
Updated
Oct 8 closing price
Net Assets
1.03B
TICIX
Price
$37.70
Change
+$0.76 (+2.06%)
Updated
Oct 9 closing price
Net Assets
161.49M
Interact to see
Advertisement

FTCNX vs TICIX

Header iconFTCNX vs TICIX Comparison
Open Charts FTCNX vs TICIXBanner chart's image
Fidelity Advisor Canada M
Price$78.25
Change+$0.04 (+0.05%)
VolumeN/A
Net Assets1.03B
Timothy Plan Israel Common Values I
Price$37.70
Change+$0.76 (+2.06%)
VolumeN/A
Net Assets161.49M
FTCNX vs TICIX Comparison Chart in %
View a ticker or compare two or three
VS
FTCNX vs. TICIX commentary
Oct 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FTCNX is a Hold and TICIX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FTCNX has more cash in the bank: 1.03B vs. TICIX (161M). TICIX pays higher dividends than FTCNX: TICIX (0.82) vs FTCNX (0.64). FTCNX was incepted earlier than TICIX: FTCNX (18 years) vs TICIX (12 years). FTCNX (1.57) and TICIX (1.52) have similar cost to investors . TICIX is a more actively managed with annual turnover of: 9.00 vs. FTCNX (8.00). FTCNX has a lower initial minimum investment than TICIX: FTCNX (0) vs TICIX (100000). TICIX annual gain was more profitable for investors over the last year : 69.02 vs. FTCNX (10.34). TICIX return over 5 years is better than : 110.97 vs. FTCNX (62.72).
FTCNXTICIXFTCNX / TICIX
Total Expense Ratio1.571.52103%
Annual Report Gross Expense Ratio1.571.52103%
Fund Existence18 years12 years-
Gain YTD20.01547.23042%
Front Load4%N/A-
Min. Initial Investment0100000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.03B161M637%
Annual Yield % from dividends0.640.8278%
Returns for 1 year10.3469.0215%
Returns for 3 years43.6471.9061%
Returns for 5 years62.72110.9757%
Returns for 10 years74.48236.1032%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMOFX47.84N/A
N/A
Patient Opportunity FI
HGOFX77.01N/A
N/A
Hartford Growth Opportunities F
UUPIX89.27N/A
N/A
ProFunds UltraEmerging Markets Inv
GGRUX15.93N/A
N/A
Goldman Sachs Strategic Growth R6
RLECX21.64-0.16
-0.73%
Russell Inv US Small Cap Equity C